Deals channel feed

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

3 years ago

A cou­ple bil­lion for Ex­sci­en­tia was on­ly part of Sanofi's AI am­bi­tions, as the Big Phar­ma adds Atom­wise to the ta­ble

3 years ago
AI

Bris­tol My­ers gets nec­es­sary clear­ance for $4.1B Turn­ing Point ac­qui­si­tion

3 years ago
R&D
Pharma

Gos­sip in Baby­lon: Dig­i­tal health com­pa­ny paints M&A ru­mors as flat-out wrong

3 years ago
Financing

Gilead doles out $280M up­front to re­gain Trodelvy rights in Chi­na, oth­er re­gion­al ter­ri­to­ries

3 years ago

'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

3 years ago

Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

3 years ago
Cell/Gene Tx
Manufacturing

Ideaya stock slashed af­ter GSK punts an op­tion

3 years ago
R&D

Ad­vent to sell stake in man­u­fac­tur­er and drug de­vel­op­er in a deal worth over $1B — re­port

3 years ago
Manufacturing

Catal­ent ac­quires North Car­oli­na CD­MO for $475M, boost­ing oral solids work

3 years ago
Manufacturing

In bid for new T cell ther­a­pies, Bris­tol My­ers inks deal with Treg play­er Gen­tiBio

3 years ago

Disc Med­i­cine goes pub­lic in re­verse merg­er with strug­gling Gem­i­ni Ther­a­peu­tics

3 years ago

On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

3 years ago
Outsourcing
Cell/Gene Tx

Mer­ck makes first big splash for Alzheimer’s drug R&D since 2017 fail, ink­ing re­search pact with Cere­vance

3 years ago

In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

3 years ago
Pharma

Sarep­ta li­cens­es next-gen AAV tech from Broad In­sti­tute in deal cov­er­ing five in­di­ca­tions — in­clud­ing Duchenne

3 years ago

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

3 years ago

Break­ing: Pfiz­er in hot pur­suit of a $5B buy­out of Glob­al Blood Ther­a­peu­tics — re­port

3 years ago

Sanofi fronts €300M to part­ner up with In­novent on Chi­na mar­ket, eye­ing quick piv­ot to com­mer­cial­iza­tion

3 years ago

Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

3 years ago

With SPAC­s' high tide long gone, Blue Wa­ter ditch­es sec­ond blank check voy­age

3 years ago
Financing

Two CD­MOs come to­geth­er as they look to ex­pand their reach in cell ther­a­py man­u­fac­tur­ing

3 years ago
Cell/Gene Tx
Manufacturing

Roche, Genen­tech place a $100M bet on fi­bro­sis, nab­bing PhII pro­gram from Kiniksa

3 years ago

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

3 years ago
Cell/Gene Tx
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times